Flying Pig Marathon to move HQ office to Walnut Hills
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Josh Hawley says he had 'good chat' with Trump after dustup over stock trading bill
WASHINGTON (AP) — Sen. Josh Hawley is brushing off President Donald Trump's quip that he's a 'second-tier' senator after the Republican's proposal to ban stock trading by members of Congress — and the president and vice president — won bipartisan approval to advance in a committee vote. The Missouri Republican told Fox News late Wednesday that it's 'not the worst thing' he's ever been called and that he and the president 'had a good chat' clearing up confusion over the bill. The misunderstanding, Hawley said, was that Trump would have to sell his Mar-a-Lago private club and other assets. 'Not the case at all,' Hawley said on 'Jesse Watters Primetime.' It was the second time in many days that Trump laid into senators in his own party as the president tries, sometimes without success, to publicly pressure them to fall in line. Earlier, Trump tore into veteran GOP Sen. Chuck Grassley of Iowa over an obscure Senate procedure regarding nominations. In a social media post, Trump called Hawley a 'second-tier Senator' who was playing into the hands of Democrats. Trump added: 'I don't think real Republicans want to see their President, who has had unprecedented success, TARGETED, because of the 'whims' of a second-tier Senator named Josh Hawley!' Stock trading bans gain support Stock trading by members of Congress has long been an issue that both parties have tried to tackle, especially as some elected officials have become wealthy while in elected office. During the COVID-19 pandemic, in particular, it was disclosed that lawmakers were trading as information about the health crisis before it became public. Insider trading laws don't always apply to the types of information lawmakers receive. Hawley's legislation with the panel's top Democrat, Sen. Gary Peters of Michigan, sailed out of the Senate's Homeland Security and Governmental Affairs Committee, after his support delivered a bipartisan vote over the objections of the other Republicans, who have majority control. GOP senators had been working with the White House on the stock trade bill, and some supported a broad carve-out to exclude the president from the ban, but it failed, with Hawley joining Democrats to block it. Trump also complained that Hawley joined with Democrats to block another amendment that would have investigated the stock trades of Democratic Rep. Nancy Pelosi, the speaker emerita, and her spouse. Paul Pelosi has been a much-watched trader, but the California lawmaker's office said she personally does not own stock. Hawley said after his conversation with Trump that the president 'reiterated to me he wants to see a ban on stock trading by people like Nancy Pelosi and members of Congress, which is what we passed.' The senator also suggested the Democratic leader should be prosecuted, but it's not clear on what grounds. Pelosi supports Hawley's bill Pelosi has said repeatedly that she's not involved in her husband's work on investments, strongly supports the bill and looks forward to voting for it in the House. 'The American people deserve confidence that their elected leaders are serving the public interest — not their personal portfolios,' she said. In a joint statement, Hawley and Peters said the legislation, called the Honest Act, builds on an earlier bill and would ban members of Congress, the president, vice president and their spouses from holding, buying or selling stock. An earlier proposal from Hawley, named after Pelosi, had focused more narrowly on lawmakers. If the bill were to become law, it would immediately prohibit elected officials, including the president, from buying stocks and would ban them from selling stocks for 90 days after enactment. It also requires the elected officials to divest from all covered investments, but not until the beginning of their next term in office — shielding the term-limited president from that requirement. 'We have an opportunity here today to do something that the public has wanted to do for decades,' Hawley told the panel. 'And that is to ban members of Congress from profiting on information that frankly only members of Congress have on the buying and selling of stock.' During the committee hearing, tensions flared as Republicans sought other approaches. Republicans fail to exempt Trump from stock trading ban GOP Sen. Rick Scott of Florida proposed one amendment that would exempt the president, the vice president, their spouses and dependent children from the legislation, and the other one that would have required a report on the Pelosi family's trades. Both were defeated, with Hawley joining the Democrats. 'We are one step closer to getting this bill passed into law and finally barring bad actors from taking advantage of their positions for their own financial gain,' Peters said in a statement. One Republican, Sen. Ron Johnson of Wisconsin, said the overall bill is 'legislative demagoguery.' 'We do have insider trading laws. We have financial disclosure. Trust me, we have financial disclosure,' Johnson said. 'So I don't see the necessity of this.' GOP's Grassley 'offended' by Trump's personal attack Trump's post criticizing Hawley comes after a similar blowback directed Tuesday night at Grassley. In that post, Trump pressured Grassley to do away with the Senate's longtime 'blue slip' custom that often forces bipartisan support on presidential nominations of federal judges. The practice requires both senators in a state to agree to push a nominee forward for a vote. Trump told Grassley to do away with the practice. 'Senator Grassley must step up,' Trump said, while claiming that he helped the senator, who was first elected in 1980, to win reelection. Grassley earlier Wednesday said he was 'offended' by what the president said. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
4 minutes ago
- Yahoo
Dupixent sales spur Sanofi growth, but profits fall short
Sanofi rode the growing sales wave for blockbuster immunology drug Dupixent (dupilumab) in Q2 but reported lower-than-expected profits after outlaying money to develop new treatments. Dupixent generated sales of €3.8bn ($4.35bn) for the company in the quarter, growing 21.1% over the same period in 2024. Sanofi expanded the sales reach of the drug with approvals in the lucrative chronic obstructive pulmonary disease (COPD) market. Dupixent's success pushed Sanofi's total net sales to €9.9bn, up 10% at constant exchange rate (CER). The French drugmaker said it expects annual sales growth in the high single-digits at constant currency rates, compared to a previous forecast of mid- to high-single-digit growth. In a conference call on 31 July, chief financial officer François-Xavier Roger said that whilst tariffs were not modelled into the guidance, little impact is expected on financials in 2025. Sanofi CEO Paul Hudson said: 'Eight years after market introduction, Dupixent grew by more than 20%, supported by the COPD launch. Based on strong sales performance in H1, we are refining our 2025 sales guidance to the upper end of our previous range. At the same time, we confirm our guidance of a strong business EPS rebound, which now includes all expenses from newly acquired businesses.' Sanofi confirmed it hopes to complete a €5bn share buyback programme in 2025, adding that around 80% has been repurchased to date. However, despite progressing its ownership control, earnings per share rose 1.9% to €1.59, lower than the €1.65 analysts estimated. Shares in Sanofi fell 1% at market open to €84.70 on the Paris exchange following the Q2 report posting, despite the strong growth for Dupixent. The profit miss was primarily due to an increase in research and development (R&D) expenses. Sanofi invested €1.9bn into the department as it seeks new drugs and vaccines to succeed Dupixent, wary of its outlook becoming too reliant on sales for the product. The R&D spending represented a 17.7% jump compared to Q2 last year. Sanofi also looked beyond in-house development in efforts to bolster its pipeline – the pharma company has had a busy July in the acquisition space. In July, the drugmaker concluded its buyout of Blueprint Medicines for $9.1bn and agreed to acquire vaccine developer Vicebio for an upfront payment of $1.5bn. In addition, Sanofi bought Dren Bio's bispecific antibody for $1.9bn in March 2025 and made a push into Alzheimer's with a $470m deal for Vigil Neuroscience in May. Despite M&A buzz, Sanofi shares have declined this year in comparison to other big pharma companies. This has been primarily due to vaccine regulation uncertainty in the US. Alongside the company's pipeline diversification strategy, Duxipent looks set to supply a healthy financial outlook for Sanofi. Analysis by GlobalData forecasts sales of €23.8bn by 2031. This is based on rising uptake for the drug and further indications it's set to gain approval in. GlobalData analysts said Dupixent addressed a biologics gap in the COPD market at the time of approval. "Dupixent sales spur Sanofi growth, but profits fall short" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
4 minutes ago
- Yahoo
XPENG Introduces A Localization Strategy And Delivers Indonesia's First Locally-Made X9
XPeng Inc. (NYSE:XPEV) is among the 12 Best EV Charging Stocks to Buy According to Hedge Funds. XPeng Inc. (NYSE:XPEV) formally launched its worldwide production strategy at the 2025 Gaikindo Indonesia International Auto Show by delivering its first locally produced X9. A close-up of a luxury electric sports sedan, its sleek body reflecting the energy of progress. Indonesia becomes the firm's first international production hub with the opening of its new factory in Purwakarta. The 800V design and 5C ultra-fast charging of its New G6 enabled a 10-80% charge in just 12 minutes. XPeng Inc. (NYSE:XPEV)'s debut into Indonesia, Southeast Asia's largest vehicle market, is a deliberate move to further cement regional dominance. The X9 combines advanced features like rear-wheel steering and a smart cockpit with family-friendly functionality. It is already popular among 30,000 families worldwide. It also became Hong Kong's best-selling MPV in June. A 2,485-mile cross-border journey from China to Jakarta was conducted to show the X9's capabilities. Chief executive officer Xiaopeng of XPeng Inc. (NYSE:XPEV) pointed out the company's effort to support Indonesia's industrial goals and its wider worldwide presence in EV innovation. It is one of the Best EV Stocks. While we acknowledge the potential of XPEV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
